Alexion shares rise after report of approach by Roche
July 30 (Reuters) - Shares of Alexion Pharmaceuticals Inc rose more than 7 percent on Tuesday following a report that Swiss drugmaker Roche Holding AG made an informal approach to the biotech company last week about a takeover.
Bloomberg, citing one unnamed person with knowledge of the matter, said that Alexion had rebuffed the approach and had retained Goldman Sachs to prepare for a possible offer.
Officials at Alexion and Roche were not immediately available to comment on the report. Goldman Sachs declined to comment.
Earlier this month, people familiar with the matter told Reuters that Roche was seeking financing for a potential bid for Alexion, whose market value neared $22 billion before Tuesday's share move.
Alexion sells Soliris, one of the world's most expensive medicines, used to treat a progressive, life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria that causes destruction of red blood cells. (Reporting by Bill Berkrot; Editing by Carol Bishopric)
- Police hunt for motive as search for Malaysian jet spans hemispheres |
- Malaysian PM says lost airliner was diverted deliberately |
- Crimeans vote on union with Russia as troops build up rapidly |
- Democrats seek ways to limit Obamacare fallout after Florida defeat
- Police make third arrest in murder of Colorado socialite